Administration, Intravesical

"Administration, Intravesical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.

Descriptor ID	D000283
MeSH Number(s)	E02.319.267.120.505
Concept/Terms	Administration, Intravesical Administration, Intravesical Intravesical Drug Administration Drug Administration, Bladder Administration, Intravesical Drug Administrations, Intravesical Drug Drug Administration, Intravesical Drug Administrations, Intravesical Intravesical Drug Administrations Intravesical Administration Administrations, Intravesical Intravesical Administrations Bladder Drug Administration Administration, Bladder Drug Administrations, Bladder Drug Bladder Drug Administrations Drug Administrations, Bladder Instillation, Bladder Instillation, Bladder Bladder Instillation Bladder Instillations Instillations, Bladder Intravesical Instillation Instillation, Intravesical Instillations, Intravesical Intravesical Instillations Intravesical Injection Intravesical Injection Injections, Intravesical Injection, Intravesical Intravesical Injections

Below are MeSH descriptors whose meaning is more general than "Administration, Intravesical".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Drug Administration Routes [E02.319.267]
Administration, Topical [E02.319.267.120]
Administration, Intravesical [E02.319.267.120.505]

Below are MeSH descriptors whose meaning is related to "Administration, Intravesical".

Below are MeSH descriptors whose meaning is more specific than "Administration, Intravesical".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Administration, Intravesical" by people in this website by year, and whether "Administration, Intravesical" was a major or minor topic of these publications.

Bar chart showing 33 publications over 16 distinct years, with a maximum of 5 publications in 2024

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
1998	2	2
2003	1	1
2008	1	1
2009	1	1
2011	2	2
2012	2	2
2013	1	1
2016	1	1
2017	2	2
2019	4	4
2020	1	1
2021	4	4
2022	3	3
2023	2	2
2024	5	5
2025	1	1

Below are the most recent publications written about "Administration, Intravesical" by people in Profiles.

Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, van der Heijden MS, Williams SB, Powles T, Chang SS, Catto JWF, Psutka SP, Guerrero-Ramos F, Xylinas E, Miyake M, Simone G, Daniel K, Sweiti H, Cutie C, Necchi A. Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Urol Oncol. 2025 05; 43(5):286-296.

View in: PubMed
Lasmanovich R, Shvero A, Kleinmann N. Upper tract urothelial carcinoma: conservative management - intraluminal adjuvant therapy, and surveillance. Curr Opin Urol. 2025 01 01; 35(1):68-74.

View in: PubMed
Abou Chakra M, Shore ND, Brown ES, Du GJ, O'Donnell MA. Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients. Urol Pract. 2024 07; 11(4):613-623.

View in: PubMed
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 07; 212(1):74-86.

View in: PubMed
Psutka SP, Veleber S, Siman J, Holt SK, Jannat S, Wright JL, Lin DW, Gore JL, Schade GR, Annen Z, Greenlee H. Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Gu?rin in Patients with High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024 Dec; 7(6):1431-1440.

View in: PubMed
Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Gu?rin for patients with Bacillus Calmette-Gu?rin-na?ve high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024 May; 20(14):891-901.

View in: PubMed
Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.

View in: PubMed
Prasad SM, Huang WC, Shore ND, Hu B, Bjurlin M, Brown G, Genov P, Shishkov D, Khuskivadze A, Ganev T, Marchev D, Orlov I, Kopyltsov E, Zubarev V, Nosov A, Komlev D, Burger B, Raju S, Meads A, Schoenberg M. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ? Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). J Urol. 2023 10; 210(4):619-629.

View in: PubMed
D'Amico MJ, Foss H, Uhr A, Rudnick B, Kloniecke E, Gomella LG. Hemorrhagic cystitis: a review of the literature and treatment options. Can J Urol. 2022 10; 29(5):11276-11283.

View in: PubMed
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement